We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New POC Biosensing Technology Improves Detection of Molecular Biomarkers

By LabMedica International staff writers
Posted on 17 Jun 2025

Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation. More...

In contrast, point-of-care diagnostics are conducted and produce results directly at the site of patient care, be it at home, in a clinic, or elsewhere. This approach enables rapid, cost-effective, and user-friendly tests that guide immediate medical decisions. Common examples already in everyday use include urine-based pregnancy tests, COVID-19 antigen kits, and glucose meters that help diabetes patients manage fluctuations in blood sugar throughout the day. Researchers are exploring innovative ways to implement such technologies within clinical environments, such as during visits to oncologists or oral surgeons. Doing so could reduce the logistical and financial strain on patients while enhancing physicians' ability to make timely, informed decisions. Researchers are now a step closer to realizing this goal through the integration of machine learning-based analysis into point-of-care biosensing platforms.

Researchers at the Carl R. Woese Institute for Genomic Biology (Urbana, IL, USA) have developed a new approach called LOCA-PRAM that simplifies biomarker detection by removing the need for skilled professionals to analyze the resulting images. This development builds upon the team’s earlier work introducing Photonic Resonator Absorption Microscopy, or PRAM—a biosensing technique capable of identifying individual biomarker molecules, such as nucleic acids, antigens, and antibodies. In contrast to conventional methods, which measure signals from large groups of molecules, PRAM offers the sensitivity to detect and analyze single molecules.

PRAM images appear as a red field dotted with black specks. Though visually straightforward, determining which specks represent AuNP-tagged biomarker molecules requires expert analysis. To make this method suitable for point-of-care settings, the researchers proposed incorporating machine learning into the image analysis. Unlike other biosensing methods that primarily detect optical signals, PRAM produces microscope images, making it well-suited for deep learning applications. To ensure high-quality data for algorithm training, the team imaged identical samples using both PRAM and scanning electron microscopy.

The AuNPs—nanoparticles roughly 1,000 times thinner than a strand of hair—appear as tiny black spots in PRAM images but are more distinctly visible under electron microscopy. Through a labor-intensive process, the researchers meticulously cross-referenced every black spot seen in the PRAM images with the corresponding features in the electron microscope images to create an accurate training dataset for the machine learning model. This resulted in a deep learning-enhanced method known as Localization with Context Awareness, integrated with PRAM. This combined platform delivers precise, real-time molecular biomarker detection without requiring the intervention of a technical specialist. When evaluated, the findings published in Biosensors and Bioelectronics showed that LOCA-PRAM outperformed standard techniques by identifying lower concentrations of biomarkers and reducing the likelihood of false positives and negatives.

“Current technologies require patients to visit hospitals to get diagnostics which takes time. A lot of people also have barriers where more appointments may not be financially or spatially feasible,” said Han Lee, first author of the study and a graduate student in the Nanosensors research group. “I think that we can make a difference by developing more point-of-care technologies that are available for people.”


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Pathology

view channel
Image: The new methyl-copying PCR method preserves DNA methylation patterns during amplification (Photo courtesy of Syndex Bio)

Novel mcPCR Technology to Transform Testing of Clinical Samples

DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.